TY - JOUR
T1 - Novel Nanomonitor ultra-sensitive detection of troponin T
AU - Barrett, Thomas W.
AU - Radha Shanmugam, Nandhinee
AU - Selvam, Anjan Panneer
AU - Kazmierczak, Steven C.
AU - Prasad, Shalini
N1 - Funding Information:
This work was presented, in part, in poster form at the Materials Research Society Conference, April 24, 2014, San Francisco, California, “Rapid and Sensitive Detection of Nano-fluidically Trapped Protein Biomarkers”. Oregon Nanoscience and Microtechnologies Institute , and Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1 RR024140 from the National Center for Research Resources (NCRR) and the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH), and the Cecil and Ida Green Endowment in Systems Biology at University of Texas at Dallas.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Troponin is the preferred biomarker for diagnosing myocardial infarction. Point of care devices have not matched the sensitivity of laboratory-based methods for measuring troponin. The Nanomonitor is a novel point-of-care device that uses the change in electrical impedance that occurs when a biomarker binds to its antibody, which is then correlated to the concentration of the target biomarker. Methods: Performance characteristics of the Nanomonitor were evaluated and compared to a standard laboratory-based method. Results: The limit of detection of the Nanomonior for troponin T was 0.0088. ng/l. Total imprecission was 2.38% and 0.85% at troponin T concentrations of 73. ng/l and 1800. ng/l. The functional sensitivity (10% coeffecient of variation) was 0.329. ng/l. The linear regression had a slope of 0.996 (95% confidence interval, 0.991, 1.002), r = 1.00, and an intercept of 15.88. ng/l (95% confidence interval, - 68.39. ng/l, 100.15. ng/l). The mean difference between the assays was - 7.54. ng/l, determined by Bland-Altman analysis. Conclusion: The Nanomonitor preliminary results have favorable performance characteristics for detecting troponin T in patient blood, provide results in 15. min, and are portable. More research is needed.
AB - Troponin is the preferred biomarker for diagnosing myocardial infarction. Point of care devices have not matched the sensitivity of laboratory-based methods for measuring troponin. The Nanomonitor is a novel point-of-care device that uses the change in electrical impedance that occurs when a biomarker binds to its antibody, which is then correlated to the concentration of the target biomarker. Methods: Performance characteristics of the Nanomonitor were evaluated and compared to a standard laboratory-based method. Results: The limit of detection of the Nanomonior for troponin T was 0.0088. ng/l. Total imprecission was 2.38% and 0.85% at troponin T concentrations of 73. ng/l and 1800. ng/l. The functional sensitivity (10% coeffecient of variation) was 0.329. ng/l. The linear regression had a slope of 0.996 (95% confidence interval, 0.991, 1.002), r = 1.00, and an intercept of 15.88. ng/l (95% confidence interval, - 68.39. ng/l, 100.15. ng/l). The mean difference between the assays was - 7.54. ng/l, determined by Bland-Altman analysis. Conclusion: The Nanomonitor preliminary results have favorable performance characteristics for detecting troponin T in patient blood, provide results in 15. min, and are portable. More research is needed.
KW - Functional sensitivity
KW - Nanotechnology
KW - Point-of-care
KW - Troponin T
UR - http://www.scopus.com/inward/record.url?scp=84922032860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922032860&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2015.01.013
DO - 10.1016/j.cca.2015.01.013
M3 - Article
C2 - 25619774
AN - SCOPUS:84922032860
VL - 442
SP - 96
EP - 101
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
SN - 0009-8981
ER -